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The porcine lymphotropic herpesviruses (PLHV) are discussed as possible risk factors in xenotransplantation because of the high prevalence of
PLHV-1, PLHV-2 and PLHV-3 in pig populations world-wide and the fact that PLHV-1 has been found to be associated with porcine post-
transplant lymphoproliferative disease. To provide structural and functional knowledge on the PLHV immediate-early (IE) transactivator genes,
the central regions of the PLHV genomes were characterized by genome walking, sequence and splicing analysis. Three spliced genes were
identified (ORF50, ORFA6/BZLF1h, ORF57) encoding putative IE transactivators, homologous to (i) ORF50 and BRLF1/Rta, (ii) K8/K-bZIP and
BZLF1/Zta and (iii) ORF57 and BMLF1 of HHV-8 and EBV, respectively. Expressed as myc-tag or HA-tag fusion proteins, they were located to
the cellular nucleus. In reporter gene assays, several PLHV-promoters were mainly activated by PLHV-1 ORF50, to a lower level by PLHV-1
ORFA6/BZLF1h and not by PLHV-1 ORF57. However, the ORF57-encoded protein acted synergistically on ORF50-mediated activation.
© 2006 Elsevier Inc. All rights reserved.Keywords: Porcine lymphotropic herpesvirus; Immediate-early transactivator; XenotransplantationIntroduction
Recently, new porcine lymphotropic gammaherpesviruses
(PLHV-1, -2 and -3) have been identified, which are highly
prevalent in domestic and feral pigs. The genomes of these
viruses are homologous to those of the human gammaherpes-
viruses Epstein-Barr virus (EBV) and human herpesvirus 8
(HHV-8), which are frequently associated with important
diseases in transplant recipients (Ehlers et al., 1999; Ulrich
et al., 1999; Goltz et al., 2002; Chmielewicz et al., 2003). EBV is
associated with post-transplantation lymphoproliferative dis-
orders (PTLD), affecting approximately 1–10% of solid organ
transplant recipients (reviewed by Razonable and Paya, 2003).
HHV-8 is tightly linked to Kaposi's Sarcoma (KS), which
occurs in up to 5% of patients receiving a transplant (reviewed
by Singh, 2000). Importantly, PLHV-1 was found to be
involved in the etiology of a lymphoproliferative disease,
affecting experimentally transplanted and immunosuppressed⁎ Corresponding author. Fax: +49 30 45472598.
E-mail address: ehlersb@rki.de (B. Ehlers).
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doi:10.1016/j.virol.2006.08.008miniature swine. This porcine disease resembled the EBV-
associated PTLD in humans (Huang et al., 2001).
Pigs are intended for use as donors of cells and organs in
xenotransplantation (Auchincloss and Sachs, 1998), and there-
fore, the xenoinfectivity of PLHV-1, -2 and -3 is an important
safety issue. However, the infectivity of the PLHV for human
cells could so far not be assessed, because lytic cell culture
systems for the PLHVare not available. Two porcine B cell lines
(L23; L52) and a cell line of probable T cell-origin (L35) had
been found to be PCR-positive for PLHV-3. Unfortunately,
attempts to stimulate PLHV lytic replication in these cell lines
with several chemicals and biological compounds, known to
activate lytic replication of EBVand HHV-8, failed (Chmielewicz
et al., 2003; Swantje Wernicke and Bernhard Ehlers, unpublished
data).
Reactivation of herpesviruses is initiated and controlled by a
few regulatory proteins encoded by viral immediate-early (IE)
genes, expressed as the first genes after primary infection or
reactivation. In EBV, the expression of either the BRLF1/Rta or
the BZLF1/Zta gene is sufficient to induce EBV lytic replication
in latently infected cells. Rta and Zta also synergize in
regulating viral gene expression, leading to a lytic cycle
135I. Lindner et al. / Virology 357 (2007) 134–148cascade (Countryman and Miller, 1985; Zalani et al., 1996;
Ragoczy et al., 1998; Ragoczy and Miller, 1999; Feederle et al.,
2000). In HHV-8, ORF50 and ORFK8/K-bZIP were identified
as homologues (Lukac et al., 1998; Lin et al., 1999). ORF50 is a
potent transcriptional activator of several viral and cellular
genes (Lukac et al., 2001; Song et al., 2001; Wang et al., 2001).
Like EBV Zta, HHV-8 K8/K-bZIP was found to bind to the
origin of lytic replication (oriLyt) of HHV-8 and to cause cell
cycle arrest at G1 phase (Lin et al., 2003; Wu et al., 2002).
However, K8/K-bZIP failed to activate HHV-8 in latently
infected cells (Lukac et al., 1999; Polson et al., 2001).
Importantly, transduction of HHV-8 ORF50/Rta into latently
infected cells with a recombinant adenovirus efficiently induced
lytic replication in many cell lines (Bechtel et al., 2003).
In a previous study, we characterized a part of the PLHV-1
genome, spanning ORF03 to ORF52, and found two genes
which revealed moderate to weak homology to ORF50/Rta
and K-bZIP/Zta of HHV-8 and EBV, respectively (Goltz et
al., 2002). If these genes were functional homologues of their
HHV-8/EBV counterparts i.e. IE transactivator genes, they
could potentially be used for reactivation of the PLHV in
latently infected cells. Therefore, structural and functional
knowledge of the putative PLHV IE genes was desired.
Here, we present further sequence characterization of
PLHV-1, -2 and -3 down to rhadinovirus ORF69 by genome
walking, sequence and splicing analyses. Three spliced genes,
encoding putative IE-transactivators, were identified and their
structure and function was analysed.
Results
Determination of novel PLHV sequences, gene arrangement
and transcription analysis
PLHV sequences have previously been amplified by genome
walking, and contiguous PLHV-1, PLHV-2 and PLHV-3
sequences of 59–73 kb have been determined (Goltz et al.,
2002, Chmielewicz et al., 2003). Here, these sequences were
extended by exactly the same methodology to 101 kb (PLHV-1),
68 kb (PLHV-2) and 98 kb (PLHV-3). The novel additional
sequence of PLHV-1 (28 kb) encompasses the third conserved
gene block of gammaherpesviruses i.e. the ORFs 52–69. The
additional sequence of PLHV-3 (38 kb) encompasses the 3′-end
of the second conserved block (ORFs 45–50), the third
conserved block (ORFs 52–69) and interspersed between both
blocks the central unconserved region with the ORFs A6/
BZLF1h, A7/BZLF2h and A8/BLLF1h. The PLHV-2 sequence
was extended over the central unconserved region until ORF52.
The potential ORFs of the PLHV downstream from ORF44
are listed in Table 1. A map of the PLHV-1 ORF arrangement is
shown in Fig. 1A. In comparison to other gammaherpesviruses,
all ORFs are most closely related to those of the wildebeest
gammaherpesvirus AlHV-1. In comparison to the human
gammaherpesviruses, nearly all PLHV ORFs are closer related
to the homologous ORFs of HHV-8 than to those of EBV.
However, the PLHV gene A7/BZLF2h is a homologue of EBV
BZLF2 which is not present in the HHV-8 genome (Table 1).PLHV-1 transcription analysis
PLHV-1 ORF50, ORFA6/BZLF1h, ORFA7/BZLF2h,
ORFA8/BLLF1h and ORF57 were analyzed by rtPCR and
RACE in order to find predicted or unkown splice variants.
PLHV-1 ORF 50
Two exons (ORF50 a+b) and a translation start in exon 50a
were predicted. Splicingwas experimentally confirmed (variant 1,
Fig. 1B). Furthermore, a second splice variant was found con-
sisting of exons 50a and 50c, the latter starting 829 bp downstream
of the splice acceptor site of exon 50b (variant 2, Fig. 1B). For this
transcript, translation was predicted to start within exon 50c with
an ATG 14 bp downstream of the splice acceptor site. The protein
would be encoded by the same reading frame as ORF50 variant 1,
therefore resulting in a shorter form of the ORF50 product. For
both variants no 5′-RACE product was found. 3′-RACE products
were foundwith transcripts ending 128 bp downstream of the stop
codon at the predicted polyA-signal.
PLHV-1 ORFA6/BZLF1h
Three exons (A6/BZLF1h a+b+c) were predicted. These
were confirmed with rtPCR as well as RACE. Additionally, we
found a second splice variant, where only the second intron was
removed (Fig. 1C). 5′-RACE products were found, resulting in
a transcript start 40 bp upstream of the ATG of the fist A6/
BZLF1h exon. 3′- RACE products were found with transcripts
ending 65 bp downstream of the STOP codon of the third exon
at the predicted polyA signal. By 3′-RACE also an unspliced
version was detected.
Interestingly, each of the three exons starts with an in-frame
ATG. In both introns stop-codons were found for the same
reading frame. Therefore, it is possible that each of the exons
of ORFA6/BZLF1h is translated to a short variant of the entire
protein. This finding is conserved between PLHV-1 and
PLHV-2. In PLHV-3, the ATG in the third exon is missing.
PLHV-1 ORFA7/BZLF2h
A single exon was predicted and confirmed with rtPCR (not
shown).
PLHV-1 ORFA8/BLLF1h
In initial computational ORF analysis we had defined two
consecutive ORFs, ORFA8/BLLF1h and ORF51 (Goltz et al.,
2002). Now, comparison of ORFA8/BLLF1h of PLHV-1 with its
homologues in PLHV-2 and PLHV-3 revealed highly uncon-
served 3′-ends, suggesting a splicing event. By rtPCR, spliced
transcripts were identified consisting of both ORFA8/BLLF1h
and ORF51. The first exon ends at 1267 bp downstream of the
ATG of ORFA8/BLLF1h, thereby removing the unconserved
end of the ORF. The second exon begins 23 bp downstream of
the ATG of the predicted ORF51 which now is obviously part of
ORFA8/BLLF1h (Fig. 1D). ClustalWanalysis of the aa sequence
encoded by this spliced product with the predicted counterparts
of PLHV-2 and -3 revealed high conservation (91% and 51%,
respectively; Table 1). By RACE analysis, no 5′-end of the
transcript could be found. A 3′-RACE product was identified
Table 1
Potential ORFs in PLHV-1, PLHV-2 and PLHV-3 and homologous ORFs in AlHV-1, HHV-8 and EBV
Pol. PLHV-1 PLHV-2 PLHV-3 AlHV-1 HHV-8 EBV Function
ORF Size
(aa)
ORF Size
(aa)
%id ORF Size
(aa)
%id ORF Size
(aa)
%id ORF Size
(aa)
%id ORF Size
(aa)
%id
_ 45 223 45 223 89.7 45 247 66.5 45 235 32.8$ 45 407 38.6$ BKRF4 217 30.9$ IE transactivator
_ 46 251 46 251 92.4 46 252 82.7 46 252 65.3 46 255 53.8 BKRF3 255 55.6 Uracil glycosylase
_ 47 142 47 142 89.5 47 142 56.3 47 168 35.4$ 47 167 29.5$ BKRF2 137 28.0$ Cell fusion protein
_ 48 498 48 508 89.8 48 473 56.5 48 419 30.1$ 48 402 20.9 BRRF2 537 28.6$ Unknown
_ 49 309 49 309 92.6 49 309 66.0 _ 49 302 23.2$ BRRF1 310 23.1 Unknown
+ 50 510 50 509 95.3$ 50 515 71.3$ 50 619 37.5$ 50 668 29.1$ BRLF1 605 24.6$ IE transactivator
50a 14 50a 14 50a 14 50a 26 50a 6 _
50b 496 50b 495 50b 501 50b 593 50b 662 _
+ A6/BZLF1 172 A6/BZLF1 174 91.3$ A6/BZLF1 183 60.4$ A6 280 33.9$ K8 237 28.8$ BZLF1 245 23.1$ IE transactivator
A6/BZLF1 a 101 A6/BZLF1 a* 103 A6/BZLF1 a 108 A6 a* 204 K8 a 158 BZLF1 a 167
A6/BZLF1 b 35 A6/BZLF1 b* 35 A6/BZLF1 b 35 A6 b* 35 K8 b 31 BZLF1 b 36
A6/BZLF1 c 36 A6/BZLF1 c* 36 A6/BZLF1 c 40 A6 c* 41 K8 c 48 BZLF1 c 43
+ A7/BZLF2 234 A7/BZLF2 234 92.8 A7/BZLF2 254 69.4$ A7 244 32.0$ BZLF2 223 32.0$ Cell fusion protein
+ A8/BLLF1 530$ A8/BLLF1 525 91.2$ A8/BLLF1 518 51.0$ A8 623 25.3$ K8.1A 228 32.3$ BLLF1/
gp220
658 23.3$ Cell attachment protein
+ A8/BLLF1 a 422 A8/BLLF1 a* 422 A8/BLLF1 a* 416 A8 a* 603 K8.1A a 141 gp220 a 503 Cell attachment protein
+ A8/BLLF1 b 108 A8/BLLF1 b* 103 A8/BLLF1 b* 102 A8 b* 20 K8.1A b 87 gp220 b 155 Cell attachment protein
_ 52 136 52 136 92.7 52 133 70.9$ 52 125 37.7$ 52 131 27.8 BLRF2 162 28.8 Capsid protein
_ 53 112 53 111 59.8 53 103 45.0 53 110 37.3 BLRF1 102 41.2$ Unknown
+ 54 294 54 294 69.7 54 298 43.2$ 54 318 30.9$ BLLF3 278 34.3$ dUTPase
_ 55 213 55 213 80.8 55 220 65.0 55 227 48.3 BSRF1 218 48.3 Unknown
+ 56 834 56 838 71.2 56 837 46.7 56 843 41.1$ BSLF1 874 38.0$ DNA replication protein
+ 57 431 57 432 78.0 57 436 44.4$ 57 455 30.5$ BMLF1 479 28.3$ Immediate-early protein
+ 57 a 17 57 a* 17 57 a 17 57 a 16 BMLF1 a 42
+ 57 b 413 57 b* 415 57 b 419 57 b 438 BMLF1 b 438
_ 58 351 58 351 71.2 58 351 44.9$ 58 357 31.1$ BMRF2 357 29.9 Unknown
_ 59 374 59 401 79.1 59 411 47.2$ 59 396 31.5$ BMRF1 404 31.5$ DNA replication protein
_ 60 304 60 305 89.2 60 305 71.2 60 305 57.1 BaRF1 302 58.9$ Ribonucleotide reductase.
small
_ 61 796 61 797 77.9 61 780 60.8$ 61 792 49.9$ BORF2 826 45.0$ Ribonucleotide reductase.
large
_ 62 350 62 340 72.4 62 334 43.4$ 62 331 35.5 BORF1 364 31.0 Assembly /
DNA maturation
+ 63 942 63 945 72.1 63 952 43.0$ 63 927 28.3 BOLF1 1239 24.4$ Tegument protein
+ 64 2422 64 2423 60.2 64 2606 33.8$ 64 2635 27.1$ BPLF1 3149 26.6$ Tegument protein
_ 65 163 65 164 74.5 65 252 38.7$ 65 170 23.1 BFRF3 176 28.8$ Capsid protein
_ 66 445 66 444 63.3 66 437 38.0$ 66 429 32.1 BFRF2 591 29.0$ Unknown
_ 67 283 67 282 76.5 67 263 58.4$ 67 271 44.7$ BFRF1 336 44.0$ Tegument protein
_ 67.5 84 67.5 90 76.5 67A 84 51.2 _ _ Unknown
+ 68 457 68 464 66.5$ 68 468 48.0$ 68 545 39.6$ BFLF1 525 38.8 Glycoprotein
(Pol.) Polarity.
(%id) percent identity.
(*) determined in silico by identification of splice sites which are positionally conserved compared to those of PLHV-1.
($) GAP program run without end gaps penalized.
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137I. Lindner et al. / Virology 357 (2007) 134–148consisting of an unspliced transcript. This product ended 2 bp
downstream of the stop codon at the predicted polyA-signal.
PLHV-1 ORF 57
rtPCR revealed two variants of ORF57, a spliced and an
unspliced form. The first exon of the spliced form ends 52 bp
downstream of the ATG of this gene, followed by an intron of
90 bp and a second exon, which starts 143 bp downstream of the
ATG (Fig. 1E).
PLHV-3 transcription analysis
PLHV-3 transcripts were analyzed by rtPCR and RACE.
Probably due to the almost complete absence of PLHV-3
transcripts in the available sample materials, splicing could not
be demonstrated for ORF50, ORFA7/BZLF2h, ORFA8/
BLLF1h and ORF57. Only for ORFA6/BZLF1h the rtPCR
was successful. The same splice variants as in PLHV-1 were
detected. RACE experiments were only successful for ORF50.
A 3′-RACE product was detected 123 bp downstream of the
stop codon at the predicted polyA-signal.
The PLHV proteins encoded by ORF50, ORFA6/BZLF1h and
ORF57, are homologous to the IE transcriptional activators of
EBV and HHV-8
The PLHV-1 proteins, encoded by the experimentally
observed spliced transcripts of ORF50 exons a+b, ORFA6/
BZLF1h exons a+b+c and ORF57 exons a+b, were multiply
aligned with the positional counterparts of PLHV-2, PLHV-3,
AlHV-1, HHV-8 and EBV.
The PLHV ORF50-encoded proteins are structurally con-
served, predominantly in their N-terminal part. The PLHV-1
protein shows an identity of 95% and 71% to its ORF50
counterparts in PLHV-2 and -3, respectively (Table 1, Fig. 2).
Similarity to AlHV-1 ORF50, HHV-8 ORF50 and EBV BRLF1
is visible only in the N-terminal part (Fig. 2). The PLHVORF50
proteins reveal multiple potential phosphorylation sites and are
rich in serine and threonine in their C-terminal part, like their
homologues in AlHV-1, HHV-8 and EBV. They also contain
potential nuclear localization signals (NLS), one at the N-
terminus (aa position 8–16) and four additional sites further
downstream (Fig. 2).
The protein, encoded by the ORFA6/BZLF1h of PLHV-1,
shows an identity of 91% and 60% to its counterparts in
PLHV-2 and -3, respectively. Highest conservation was seen in
the part of the protein encoded by exon B (Fig. 3A). The
sequence similarity to A6 of AlHV-1, K8/K-bZIP of HHV-8
and BZLF1 is weak (Table 1). However, short conserved
regions with potential importance for protein function were
identified. A leucine-zipper motif was found between L138 and
L159, preceeded by a region of basic amino acids (Fig. 3A). A
stretch of basic amino acids, combined with a leucine-zipper
motif, has been identified in many cellular transcription factors
and has been shown to be responsible for DNA binding (Hurst,
1995). In addition, similar structures were identified in K8/K-
bZIP of HHV-8 and in BZLF1 of EBV (Lin et al., 1999;Flemington and Speck, 1990). Therefore, an alignment of the
ORFA6/BZLF1h-encoded proteins of AlHV-1A6, HHV8K8/K-
bZIP and EBV BZLF1, as well as the human transcription
factors FOS, JUN, CREB and CEBA, was performed. It shows,
that the whole motif is conserved (Fig. 3B). A second region of
mainly basic amino acids, conserved in gammaherpesvirus and
cellular transcription factors, was seen between R67 and R85. In
HHV-8, a part of this regionwas identified as NLS (Portes-Sentis
et al., 2001).
The ORF57 encoded protein of PLHV-1 shows an identity of
78% to its counterpart in PLHV-3. The sequence similarity to
AlHV-1 ORF57, HHV-8 ORF57 and EBV BMLF1 is moderate
in the N-terminal part and higher in the C-terminal part. A
leucine-zipper motif was found between L315 and L336. A
potential nuclear localization signal was found at amino acid
(aa) position 67–70 (Fig. 4 and Table 1).
The three proteins were also analysed with the PSORT
module of the HUSAR program package. In each case nuclear
localization was strongly predicted (70% to 83% probability).
Expression and subcellular localization of the ORF50, ORFA6/
BZLF1h and ORF57 encoded proteins of PLHV-1
To determine the cellular localization of the proteins encoded
by ORF50, A6/BZLF1h and ORF57, we constructed expression
vectors with epitope tags fused to the N or C terminus of the
proteins. PLHV-1 ORF50 was cloned from genomic DNA into
the vector pCMV-myc, creating an N-terminal fusion of ORF50
to a c-myc-tag (pCMV50-myc). ORFA6/BZLF1h was fused at
the N- or C-terminus with a haemagglutinin (HA) tag and cloned
in the vector pCR3.1-uni (pCRA6/BZLF1h-HAn and pCRA6/
BZLF1h-HAc, respectively). Likewise, ORF57 was cloned
(expression plasmids pCR57-HAn and pCR57-HAc).
To verify that all constructs were coding for functional
proteins we analyzed them by Western blotting. 293 cells were
transiently transfected with the vectors pCMV50-myc, pCRA6/
BZLF1h-HAn and pCR57-HAn expressing N-terminally tagged
fusion proteins. 48 hours after transfection, cells were
harvested, and cell lysates were examined by immunoblotting.
Expression of the ORF50 protein was detected with anti-c-myc
antibody in cells transfected with pCMV50-myc. Two protein
bands with different intensity at approximately 72 kDa and
38 kDa were seen (Fig. 5A). The upper, most intensive band
most likely corresponds to ORF50 protein while the lower,
fainter band probably represents a degradation product. The
observed 70–72 kDa of the ORF50 protein differs from the
predicted size (60,3 kDa). Most likely, this is due to protein
modifications, as demonstrated earlier for the HHV-8 ORF50
protein (Lukac et al., 1999; Gwack et al., 2003). The molecular
mass of the ORFA6/BZLF1h protein expressed from pCRA6/
BZLF1h-HAn was approximately 24 kDa, matching quite
closely the predicted size of 21,9 kDa (Fig. 5B). The size of the
ORF57 protein in cells transfected with pCR57-HAn was
approximately 57 kDa, nearly consistent with the predicted size
of 51,2 kDa (Fig. 5B).
For subcellular localization of the proteins, 293 cells
were transiently transfected, and the proteins were detected
138 I. Lindner et al. / Virology 357 (2007) 134–148by immunofluorescence using confocal laser scanning
microscopy. The ORF50-myc fusion protein was localized
in the nucleus of transfected cells (Fig. 6A). The samelocalization pattern was seen for the N- or C-terminally HA-
tagged fusion proteins of ORFA6/BZLF1h and ORF57
(Fig. 6B–E).
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transcriptional activity
To explore the potential of PLHV-1 ORF50, ORFA6/
BZLF1h and ORF57 to regulate the expression of PLHV-1
genes, we examined their ability to transactivate a selection of
PLHV-1 IE, early and late gene promoters. PK15 and 293
cells were cotransfected with one of the promoter plasmids
pGL-PA6pr, pGL-P50pr, pGL-P57pr, pGL-P59pr, pGL-P9pr,
pGL-P8pr and either with the control vector pCR-NS or with
one of the expression vectors pCR-50, pCR-A6/BZLF1h or
pCR-57.
ORF50
Fig. 7A shows that ORF50 was able to activate all PLHV-1
promoters in two different cell lines. The promoters of ORFA6/
BZLF1h and the glycoprotein B gene (ORF8) were most
strongly upregulated in 293 cells (144-fold and 289-fold,
respectively). ORF50 transactivated the ORF59 promoter to 94-
fold, the DPOL (ORF9) promoter to 34-fold and the ORF57
promoter to 39-fold. ORF50 also stimulated its own expression
(5-fold), similarly to HHV-8 ORF50 and EBV BRLF1 (Deng
et al., 2000; Ragoczy and Miller, 1999).
The results obtained in PK15 cells revealed slight differences.
A weaker stimulation of PLHV-1 promoters was generally
observed. The highest activation values were also measured for
the promoters of A6/BZLF1h and glycoprotein B, but in contrast
to 293 cells the gB promoter was less responsive to PLHV-1
ORF50 than the A6/BZLF1h promoter. This suggests that the
composition of cellular factors, contributing to ORF50 transacti-
vation, differs between 293 and PK15 cells. To demonstrate that
the activation of the promoters by ORF50 is dose-dependent,
PK15 and 293 cells were cotransfected with increasing amounts
of the expression plasmid pCR-50 (150–600 ng) and constant
amounts of one of the promoter plasmids. Fig. 7B shows that
ORF50 transactivates the promoters of ORFA6/BZLF1h, ORF50,
ORF57 andORF59 in a dose-dependentmanner. For example, the
A6/BZLF1h promoter was upregulated from 64-fold to 225-fold
(150 to 600 ng of pCR-50, respectively).
ORFA6/BZLF1h
Fig. 8A shows the activation of the PLHV-1 promoters by
ORFA6/BZLF1h. Compared to ORF50, ORFA6/BZLF1h sti-
mulated the transcription of PLHV-1 genes to a lesser extent. In
293 cells, A6/BZLF1h stimulated its own promoter 8.5-fold.
The other promoters were upregulated 2.5- to 5-fold. ThisFig. 1. ORF map and results of splicing analysis. (A) Map of the open reading frames
arrows indicate ORFs found in two or all three subfamilies of the herpesviruses. Ye
indicate ORFs specific for PLHV-1. A scale in kb is given above the genome. Base 1
position is not the start of a linear genome of PLHV-1, which has not yet been determi
(B–E) Results of RACE and rtPCR experiments for the ORF50, ORFA6/BZLF1h,
colours and symbols is given in the box behind panel C (ORFA6/BZLF1h). The resu
“RACE” behind every line of the figures. The predicted splice products are given in gr
shown above the scale. Position 1 in each figure is the first coding base. (B) For the s
the designation “in frame ATG”. Only 5′-RACE products were detected. (C) Splicin
for both ends. (D) ORFA8/BLLF1h was shown to be a splice product of two ORFs. T
BLLF1h. No 3′-RACE product was detected for ORFA8/BLLF1h. (E) A spliced and
performed.moderate stimulation of PLHV-1 gene expression was also
observed in PK15 cells. Here, the transactivation values were
ranging from 1.5- to 3-fold. When 293 cells were cotransfected
with increasing amounts of pCR-A6/BZLF1h, a dose-dependent
transactivation of A6/BZLF1h, ORF50, ORF57 and ORF59 was
also observed (Fig. 8B).
ORF57
In contrast to ORF50 and ORFA6/BZLF1h, PLHV-1 ORF57
did not activate the PLHV-1 promoters in PK15 or 293 cells.
Only in 293 cells, a modest transactivation of the ORF57
promoter (1,4-fold) was measured with the addition of 600 ng
pCR-57. None of the values was exceeding those measured with
the control vector pCR-NS (data not shown).
Since the ORF57 protein of HHV-8 had been reported to
enhance the transactivation activity of HHV-8 ORF50 (Malik
et al., 2004b), we analysed whether PLHV-1 ORF57 exhibits
a similar effect. We expressed both proteins together with the
ORF59 promoter-driven luciferase reporter construct, that we
had shown to be strongly upregulated by ORF50. PK15 cells
were cotransfected with increasing amounts of ORF57 (150–
600 ng) and a constant amount of ORF50 (300 ng) together
with the reporter plasmid (Fig. 9A). An opposite experiment
with increasing amounts of ORF50 and a constant amount of
ORF57 was also performed (Fig. 9B). ORF57 alone had no
effect on ORF59-promoted luciferase expression, ORF50
alone activated reporter expression 15- to 58-fold (150 to
600 ng of expression plasmid). When ORF50 was coex-
pressed with ORF57, the ORF59 promoter was much stronger
upregulated than by ORF50 alone. For example, cotransfec-
tion of 300 ng pCR-57 plasmid with 150 ng pCR-50 plasmid
resulted in a strikingly enhanced upregulation (85-fold)
compared to 300 ng pCR50 alone (15-fold). This synergistic
effect was seen in both types of experiments (Fig. 9).
Discussion
Putative IE-transactivators were found to be encoded by the
genomes of PLHV-1, -2 and -3. This was revealed on the
nucleic acid sequence level through sequence, splicing and
RACE analyses. The selection of appropriate substrates for
splicing analyses was difficult, and is reflected by the nearly
complete failure to detect spliced PLHV-3 transcripts in the
PLHV-3-positive porcine cell line L35. The lymph node tissue
from PLHV-1-positive pigs, suffering from PTLD, was in our
hands the only suitable material. The spliced transcriptsof the 101 kbp genome stretch of PLHV-1. The ORFs are shown as arrows. Black
llow arrows indicate ORFs described only for gammaherpesviruses, red arrows
is the first base of the genome stretch so far determined by genome walking. This
ned. The genome region comprising ORF 50-ORFA7 is shown in magnification.
ORFA8/BLLF1h and ORF57 are shown in summary. An explanation for lines,
lts for each gene are separated in rtPCR and RACE results, indicated as “rt” or
een below the base pair scale. The positions of the ATG and the poly-A signal are
econd splice variant of ORF50 another start codon was predicted as indicated by
g was experimentally confirmed as predicted and RACE products were detected
he second one was formerly designated as ORF51 and is now exon b of ORFA8/
an unspliced version of ORF57 was found. RACE experiments have not been
Fig. 2. Multiple alignment of PLHV ORF50-encoded proteins and homologues. With the exception of ORF BRLF1 of EBV, all proteins are translated from a spliced
transcript. Identical and similar amino acids are boxed, the former also typed in bold. Exons A and B are separated by a bold line. Regions with an accumulation of
lysine and arginine, representing potential NLS, are boxed with a bold line and numbered I–V.
140 I. Lindner et al. / Virology 357 (2007) 134–148demonstrated earlier for ORF50 and ORFA6/BZLF1h by RT-
PCR (Goltz et al., 2002), were now verified by RACE. In
addition, RT-PCR and RACE served to demonstrate the spliced
nature of the A8/BLLF1h gene and the ORF57 gene. The
homologous genes in PLHV-2 and PLHV-3 revealed conservedsplice sites in silico and the splicing of PLHV-3 ORFA6/
BZLF1h was demonstrated by RT-PCR. This strengthened our
observations on ORFA6/BZLF1h splicing in PLHV-1.
Several lines of evidence showed that ORF50 and ORFA6/
BZLF1h are putative IE-transactivators. First, it can be
Fig. 3. Multiple alignment of PLHV ORFA6/BZLF1h-encoded proteins and homologues. (A). All proteins are translated from a spliced transcript with three exons.
Identical and similar amino acids are boxed, the former also typed in bold. Exons A, B and C are separated by a bold line. A potential NLS is boxed with a bold line. A
leucine-zipper motif is marked with black arrowheads. (B) A part of the PLHV ORFA6/BZLF1h-encoded protein is multiply aligned with homologous viral and
cellular proteins. A region of basic amino acids is marked with a black bar, the leucine-zipper motif with black arrowheads.
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potential nuclear localization signals were found and immun-
fluorescence assays located them in the nucleus. Second,
PLHV-1 ORF50 was identified as a positional and structural
homologue of EBV BRLF1/Rta and HHV-8 ORF50/Rta. The
known ORF50/Rta genes are well conserved among the
gammaherpesviruses and share one common feature: the
second exon of ORF50 is spliced to the first exon by
removing an intron carrying ORF49. This splicing event is
also conserved for PLHV-1 ORF50. For EBV, both BZLF1
and BRLF1 are independently able to activate the virus lytic
cycle (Ragoczy et al., 1998; Schwarzmann et al., 1998). In
HHV-8, MHV-68 and HVS, the ORF50 protein was shown to
be alone sufficient to disrupt latency (Sun et al., 1998; Lukac
et al., 1998; Wu et al., 2000; Goodwin et al., 2001). In line
with this knowledge, PLHV-1 ORF50 was able to transactivate
different PLHV-1 promoters in a porcine and a human cell
line. PLHV-1 ORF50 also regulated its own promoter,
consistent with results from autostimulation of HHV-8
ORF50 and EBV BRLF1 (Deng et al., 2000; Ragoczy and
Miller, 1999). To study the action of ORF50 on PLHV
reactivation, the protein was expressed in a PLHV-positive cellline (L23). Unfortunately, reactivation was not observed (data
not shown). This is in accord with earlier unsuccessful
experiments, using chemical reagents like TPA or n-Butyrate
as stimulants for lytic replication in the cell lines L23, L35
and L52 (B. Ehlers and S. Wernicke, unpublished data). It is
concluded that these cell lines may not be suitable as targets
for lytic reactivation. Interestingly, in experiments reported by
Santoni et al. (2006), PLHV-1 ORF50 was able to tran-
sactivate the heterologous ORF50 and ORF57 promoters of
HHV-8 to high levels but not the orthologous EBV pro-
moters. Vice versa, HHV-8 ORF50 strongly transactivated the
PLHV-1 ORF50 and ORF57 promoters. The orthologous
EBV BRLF1 also activated the promoters, but to a lesser
extent. Finally, transfection of PLHV-1 ORF50 into the BC-3
cell line, latently infected HHV-8, resulted in upregulation of
the most abundant transcript of early viral replication (T1.1),
indicating lytic reactivation of HHV-8. These data suggest,
that PLHV-1 ORF50 could be the lytic switch protein in
PLHV-1 replication too. Further experiments are needed for to
clarify this issue.
Alignment of PLHV-1 A6/BZLF1h with related proteins
from other gammaherpesviruses identified a leucine-zipper
Fig. 4. Multiple alignment of PLHV ORF57-encoded proteins and homologues. All proteins are translated from a spliced transcript. Identical and similar amino acids
are boxed, the former also typed in bold. Exons A and B are separated by a bold line. The potential NLS is boxed. The leucine-zipper motif is marked with black
arrowheads.
Fig. 5. Expression of ORF50, ORFA6/BZLF1h and ORF57. 293 cells were transfected with expression plasmids pCMV50-myc (A), pCRA6/BZLF1h-HAn or pCR57-
HAn (B). 48 hours after transfection cell extracts were isolated and proteins were separated on SDS-10% polyacrylamide gels and analyzed by Western blotting. Viral
proteins were detected with anti-c-myc (A) or anti-HA (B) primary antibodies and peroxidase-conjugated anti-mouse IgG (see Materials and methods). As negative
controls, empty vectors pCMV-myc and pCR-NS were used.
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Fig. 6. Localization of the ORF50-, ORFA6/BZLF1h- and ORF57- encoded proteins of PLHV-1 in the nucleus of 293 cells. 293 cells were transfected with pCMV50-
myc (A), pCRA6/BZLF1h-HAn (B), pCRA6/BZLF1h-HAc (C), pCR57-HAn (D) or pCR57-HAc (E). 48 h post transfection cells were harvested and confocal analysis
was performed, using mouse anti-c-myc (A), and mouse anti-HA (B–E) primary antibodies followed by rhodamine-red-conjugated anti-mouse IgG secondary
antibodies (left). DNA was stained with DAPI (middle), and merged images are shown to the right.
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known transcriptional activators (EBV BZLF1, Jun, Fos) is
involved in homodimerization (Flemington and Speck, 1990;
Lin et al., 1999; Sinclair, 2003). Binding of A6/BZLF1h to
DNAwas so far not studied but the modest transactivation of IE,
early and late PLHV-1 promoters suggest that A6/BZLF1h is atranscriptional activator. In contrast to EBV BZLF1 that
activates the expression of several viral genes followed by
lytic replication of EBV, HHV-8 K8/K-bZIP was not found to
have transactivation activity or to disrupt latency (Lukac et al.,
1999; Polson et al., 2001). Therefore, HHV-8 K8/K-bZIP was
proposed to play an opposite role, acting as a repressor of HHV-8
Fig. 7. Transient transcriptional activation of PLHV-1 promoters by ORF50.
(A) 293 and PK15 cells were cotransfected with pCR-50 and different
reporter constructs (see Methods). Cell extracts were analyzed for luciferase
and β-galactosidase activities 48 h post transfection. Fold activation was
calculated by dividing the normalized firefly luciferase activity stimulated by
ORF50 through that stimulated by the control vector pCR-NS. Normalized
luciferase activity of pCR-NS was assigned an activity of 1. Results are the
average of duplicate samples in 5 independent experiments± standard
deviations. (B) 293 cells were cotransfected with the reporter plasmids
pGL-PA6pr, pGL-P50pr, pGL-P57pr or pGL-P59pr and increasing amounts of
pCR-50. Cell extracts were analyzed as described for panel A. Results are the
average of duplicate samples from 3 transfection experiments±standard
deviations.
Fig. 8. Transient transcriptional activation of PLHV-1 promoters by ORFA6/
BZLF1h. (A) 293 and PK15 cells were cotransfected with pCR-A6/
BZLF1h and different reporter constructs (see Methods). Cell extracts were
analyzed for luciferase and β-galactosidase activities 48 h post transfec-
tion. Fold activation was calculated as described as in legend of Fig. 7.
(B) 293 cells were cotransfected with the reporter plasmids pGL-PA6pr,
pGL-P50pr, pGL-P57pr or pGL-P59pr and increasing amounts of pCR-A6/
BZLF1h. Cell extracts were analyzed as described for panel A. Results are
the average of duplicate samples from 3 transfection experiments±standard
deviations.
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(2003) reported that K8/K-bZIP interacted with ORF50 and
repressed the transcriptional activity of ORF50 in a promoter-
dependent manner. To address the question whether A6/
BZLF1h could also modulate the transcriptional activity of
ORF50, we analyzed the activity of different promoters by
coexpression of PLHV-1 ORF50 and A6/BZLF1h. First results
indicate that A6/BZLF1h is able to influence the transcriptional
activity of ORF50 in a promoter-specific and cell-specific
manner (Iris Lindner, Bernhard Ehlers und Michael Goltz,
unpublished data) and suggest that A6/BZLF1h could play a
similiar role like HHV-8 K8/K-bZIP. To further strengthen this
hypothesis direct interaction between these proteins will have to
be studied.
PLHV-1 ORF57 was found to be the structural and
positional homologue to known posttranscriptional regulators
in other herpesviruses, including ICP27 of HSV, BMLF1 ofEBV and ORF57 of HHV-8. A counterpart of ORF57 is
present in every herpesvirus sequenced, indicating the
importance of this viral protein (Buisson et al., 1989, 1999;
Bello et al., 1999; Gupta et al., 2000; Malik et al., 2004a;
Whitehouse et al., 1998b). The ORF57 homologues affect
RNA splicing and transport posttranscriptionally. For example,
HSV ICP27 is a transcriptional and post-transcriptional
regulator, influencing pre-mRNA processing and promoting
nuclear export of viral RNAs (Sandri-Goldin, 1998). Here we
show that PLHV-1 ORF57 is located in the nucleus and is
spliced like its homologues in EBV and HHV-8. PLHV-1
ORF57 was not able to transactivate different PLHV-1
promoters, except a moderate stimulation of its own expres-
sion. In contrast, coexpression with ORF50 strongly increased
ORF59 gene expression. The increase markedly exceeded the
expression which was generated by ORF50 alone. In HHV-8,
ORF57 was shown to act synergistically with ORF50 to
activate transcription of the PAN/T1.1. and Kaposin promoters
in luciferase reporter gene assays (Kirshner et al., 2000). In
Fig. 9. ORF57 augments ORF50 mediated expression from the ORF59
promoter. (A) PK15 cells were transiently cotransfected with increasing
amounts of pCR-57 (150–600 ng), a constant amount of pCR-50 (300 ng)
and the reporter plasmid pGL-p59. All firefly luciferase activities were
normalized to the corresponding β-galactosidase activities. Fold activation
was calculated as described in legend of Fig. 7. Results are the averages of
duplicate samples from 3 transfection experiments±standard deviations. (B)
Transient reporter assays were performed with PK15 cells cotransfected with
increasing amounts of pCR-50 (150–600 ng), a constant amount of pCR-57
(300 ng) and the reporter plasmid pGL-p59. Cell extracts were analyzed as
described for panel A. Results are the average of duplicate samples from 3
transfection experiments±standard deviations.
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resulting in upregulation of the ORF50 promoter activity, was
demonstrated (Malik et al., 2004b). In accord with these
reports our data suggest, that also PLHV-1 ORF57 influences
the transcriptional activity of ORF50. Finally, ORF57 gene
expression was stimulated by ORF50. This was also demon-
strated for several other gammaherpesviruses, indicating a
conserved functionality (EBV: Gruffat et al., 1992); HHV-8:
Wang et al., 2001; HVS: Whitehouse et al., 1998a; MHV-68:
Liu et al., 2000).
In summary, key genes for the induction of PLHV lytic
replication were found. These genes can now be tested for their
potential to reactivate in vitro PLHV from latency in suitable
cell lines and thus will help to elucidate further the pathogenic
potential of the PLHV.Materials and methods
Determination of PLHV sequences
Sequences of PLHV-1, PLHV-2 andPLHV-3were determined
from a lymph node of a PTLD-affectedminiature pig (PLHV-1), a
tonsil of a hunted wild boar (PLHV-2) and a spleen of a slaughter
house pig (PLHV-3) with the help of genome walking and PCR
amplification using degenerate primers essentially as described
(Goltz et al., 2002; Chmielewicz et al., 2003).
Nucleotide and protein sequence analysis
Sequence files were assembled with the Seqman module of
the Lasergene software (GATC, Konstanz, Germany). BLAST
searches were performed at the NCBI database. ORF prediction
and calculation of identity values were performed with
MacVector (Version 8.0, Oxford Molecular Group). Multiple
sequence alignments of individual proteins were performed
with the clustalW module of MacVector. ORF designation was
carried out as described (Goltz et al., 2002).
Nucleotide sequence accession numbers and virus
abbreviations
The accession numbers for the 101 kbp sequence of PLHV-1,
the 68 kb sequence of PLHV-2 and the 98 kb sequence of PLHV-3
are AF478169, AY170317 and AY170316, respectively.
RT-PCR and RACE
Random primed cDNA was prepared from 1.2 μg of total
cellular RNA from PLHV-1-positive lymph node tissue (Goltz
et al., 2002) and the PLHV-3-positive cell line L35 (ECAAC,
Wiltshire, UK) (Chmielewicz et al., 2003), using the Super-
Script™ First-Strand Synthesis System (Gibco BRL, Gaithers-
burg, USA) according to the manufacturer's instructions.
Random hexamer oligonucleotides were used to prime the
reverse transcriptase to the RNA. PCR was performed with
HotStarTaq (Qiagen, Hilden, Germany) according to the
manufacturer's instructions. The reactions were denatured for
15 minutes at 95 °C, followed by 36 cycles of 10 seconds at
95 °C, 30 seconds at 55 °C, and 30 seconds at 72 °C. The thermal
cycling was concluded with an incubation at 72 °C for 5 minutes.
For the detection of spliced transcripts nested PCR
reactions were performed with 1 μl of 1:2 diluted oligo-dT-
cDNA as starting template using AmpliTaq Gold as described
above (Sequence determination) with an annealing temperature
of 57 or 58 °C and an elongation time of 3 min.
5′ and 3′ RACE was carried out with the FirstChoice® RLM-
RACE Kit (Ambion, Cambridgeshire, UK). The amplification
products were sequenced directly as described above.
Recombinant plasmids
The full-length forms of ORFA6/BZLF1h and ORF57, and
the larger spliced form of ORF50 (exons a+b) were cloned into
Table 2
Primers used for cloning of PLHV-1 genes
Primer Sequence (5′→3′) Size of PCR product (bp)
ORF50-F CATCAATATGGATAGCCTAC 1546
ORF50-B ATCTATTTACAGAACCAGTC
ORFA6/BZLF1h-F TTAGACAACTATGAGTGATAACTCTGCTA 725
ORFA6/BZLF1h-B AACCCTAGGTAACAGATTTAGTCTACTT
ORF57-F CAAATGCAACAATAACAGAC 1387
ORF57-B TTTACTATTTCCTTTTTACA
ORF50-myc-F CGGAATTCGGATGGATAGCCTACAAAAAATGACAC 2505
ORF50-myc-B TCCGCTCGAGTTACAGAACCAGTCTTTGGGCTAC
ORFA6/BZLF1h-HAn-F ATGATGGAATATCCTTATGACGTTCCTGACTATGCCACGAGTGATAACTCTGCTATGACAG 738
ORFA6/BZLF1h-HAn-B CTATTTAGTCTACTTGAACAAATTGAGTATCTGGA
ORFA6/BZLF1h-HAc-F ATGATGGGTGATAACTCTGCTATGACAG 731
ORFA6/BZLF1h-HAc-B TCAGGCATAGTCAGGAACGTCATAAGGATAGTAGTCTACTTGAACAAATTGAGTATCTGGA
ORF57-HAn-F ATGATGGTTTATCCTTATGACGTTCCTGACTATGCCACCACGGCACAAGAGGCAATA 1447
ORF57-HAn-B GAGCATGTCTTAGTTTTATTTACTATTTC
ORF57-HAc-F ACCATGGCACAAGAGGCAATA 1416
ORF57-HAc-B TTAGGCATAGTCAGGAACGTCATAAGGATATTTCCTTTTTACAAGGGGAAA
The underlined regions show the HA-tag.
146 I. Lindner et al. / Virology 357 (2007) 134–148the expression vector pCR3.1-uni (Invitrogen, Carlsbad, USA).
PolyA-RNA and DNA were extracted from lymph nodes of
miniature swine positive for PLHV-1. After synthesis of cDNA
from polyA-RNA, the spliced and full-length genes were
amplified from cDNA and DNA by PCR, using primers listed
in Table 2. The PCR fragments were cloned into pCR3.1-uni
and were denoted pCR-50, pCR-A6/BZLF1h and pCR-57. As
a negative control, a nonsense fragment of 32 bp was cloned
into pCR3.1-uni, obtaining the recombinant plasmid pCR-
NonSense (pCR-NS). Plasmids pCRA6/BZLF1h-HAn and
pCRA6/BZLF1h-HAc, expressing an N-terminal and C-
terminal haemagglutinin fused with the full-length ORFA6/
BZLF1h were constructed by cloning ORFA6/BZLF1h DNA
into pCR3.1-uni amplified with primers (Table 2) containing
the HA-tag. N- or C-terminally HA-tagged ORF57 proteins
were cloned in the same way, resulting in the expression
plasmids pCR57-HAn and pCR57-HAc. Cloning of the full-
length ORF50 into the EcoRI/XhoI site of pCMV-myc (BD)
resulted in pCMV50-myc, expressing N-terminal c-myc tagged
ORF50. The promoter sequences of several IE, early and late
genes of PLHV-1 were cloned into the SmaI site of the reporter
plasmid pGL3-basic (Promega, Madison, USA) upstream of aTable 3
Primers used for cloning PLHV-1 promoters
Primer Sequence (5′→3′)
ORF50pr-F TAACCCGGGAGGTTC
ORF50pr-B TAACCCGGGCCCTTC
ORFA6/BZLF1hpr-F TAACCCGGGAGCCGA
ORFA6/BZLF1hpr-B TAACCCGGGTGTCTA
ORF57pr-F TAACCCGGGAGACTC
ORF57pr-B TAACCCGGGGGTTAC
ORF59pr-F TAACCCGGGGTCTCC
ORF59pr-B TAACCCGGGTAACAT
ORF09/DPolpr-F TAACCCGGGGACGTC
ORF09/DPolpr-B TAACCCGGGAATACG
ORF08/gBpr-F TAACCCGGGGAATGT
ORF08/gBpr-B TAACCCGGGAAGAGC
Nucleotides in bold characters represent the XmaI restriction site used for cloning Ppromoterless luciferase gene. These were the promoters of the
IE and early genes ORF50, ORFA6/BZLF1h, ORF57, ORF59
and ORF09 (DNA polymerase gene). As a late gene the
promoter of ORF08 (glycoprotein B gene) was used. DNA
fragments were obtained by PCR using DNA from PLHV-1
infected porcine lymph nodes and primers listed in Table 3.
Cell culture and transfections
Human 293 cells and porcine PK15 cells were cultured in
DMEM medium (Life Technologies, Paisley, UK) supplemen-
ted with 5% (293) or 10% (PK15) inactivated fetal bovine
serum (FBS), 100 U penicillin ml−1 and 100 μg streptomycin
ml−1. All cells were grown at 37 °C in the presence of 5% CO2.
Cell lines were passaged 24 h before transfection to obtain
optimal cellular density.
To perform the luciferase and β-galactosidase assays, 293
and PK15 cells were seeded in 24 well plates (5×104 cells per
well) and transfected transiently using Effectene (Qiagen,
Hilden, Germany) or GenePorter 2 (Peqlab, Erlangen, Ger-
many). Cells were cotransfected with 100 ng of the reporter
plasmids pGL-PA6pr, pGL-P50pr, pGL-P57pr, pGL-P59pr,Size (bp)
AGTTTCAGGACACTGG 1215
TTTTATCCATGGGTGT
AGTCAGAGTCAAAGC 1305
ACAAGTTTAACCATCAAG
CCACCAGGTTTACTTT 1043
AACTGAATTCCTATGCTC
ATAACTCTTGCCGTATT 1240
GTCATCCTTTCAGTGTCTA
AGGCAGAATCTACTACTG 1478
GGTTAAAGAACGACATAT
CCTACAGATGAGGCACC 1299
ATACAGGTCTTTAAATATCC
LHV-1 promoters.
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sion plasmids pCR-50, pCR-A6/BZLF1h or pCR-57. Control
cells were cotransfected with equal amounts of pCR-NS and the
reporter plasmids in order to normalize total DNA amounts for
each transfection. Data shown are the result of at least five
experiments performed in duplicate for each reporter assay.
For cotransfection of cells with both expression plasmids
pCR-50 and pCR-57 in addition to one of the promoter
plasmids, only GenePorter 2 was used as transfection reagent.
Cells were cotransfected with increasing amounts of pCR-57
(150–600 ng), a fixed amount of pCR-50 (300 ng) (or vice
versa) and the reporter plasmid pGL-P59pr.
Immunofluorescense assay
293 cells were plated on glass coverslips in 24 well plates at a
density of 5×104 cells/ml and transfected with pCMV50-myc
or plasmids expressing N- or C- terminally HA-tagged ORFA6/
BZLF1h (pCRA6/BZLF1h-HAn; pCRA6/BZLF1h-HAc) or
ORF57 (pCR57-HAn; pCR57-HAc) after 24 hours. 48 h post
transfection cells were washed with phosphate-buffered saline
(PBS) and fixed with 3,7% paraformaldehyde, 0,1% Triton-
X100 in PBS for 20 minutes at room temperature. Cells were
washed with PBS and blocked with 0,1% Tween 20, 1% BSA in
PBS for 1 h at room temperature. Cells were then incubated with
mouse anti-c-myc (Sigma, St. Louis, USA) or mouse anti-HA
(Hiss Diagnostics, Freiburg, Germany) primary antibodies for
1 h at room temperature. Coverslips were washed in PBS, 0,1%
Tween 20 three times for 10 minutes and incubated with a
rhodamine-red-conjugated anti-mouse secondary antibody
(Dianova, Hamburg, Germany) again for 1 h at room
temperature. Cells were washed again in 0,1% Tween 20 in
PBS three times for 10 minutes. After washing the coverslips
three times with Milipore-Water, cells were incubated with
DAPI (Merck, Darmstadt, Germany) for 10 minutes. Prior to the
addition of Immu-Mount (Thermo Shandon, Pittsburgh, USA)
mounting solution, cells were washed again in Milipore water
two times. Images were captured by confocal laser scanning
microscopy (Zeiss, Jena, Germany).
Western immunoblotting
293 cells were seeded at a density of 2×105 cells/ml in 60mm
dishes and transfected with plasmids pCMV50-myc, pCRA6/
BZLF1h-HAn or pCR57-HAn after 24 hours. 48 hours post
transfection cells were washed twice with ice-cold PBS, lysed
with lysis buffer (150 mMNaCl, 20 mM Tris HCl pH 7,5, 5 mM
MgCl2, 1 mM EDTA, 1% NP40), supplemented with a protease
inhibitor cocktail (Roche, Germany) and Benzosase nuclease
(Novagen,Madison, USA). The lysis reaction was performed for
one hour on icewith brief shaking of the dishes every 10minutes.
After vortexing the samples for 1 minute, lysates were
centrifugated for 5 min at 13000 rpm (17900 g), 4 °C and
supernatants were collected. The lysates were then boiled in
SDS-β-mercaptoethanol sample buffer for 5 min prior to
electrophoresis through a 10% polyacrylamide gel. After
electrophoresis, gels were transferred to PVDF membrane byelectroblotting for 1 hour and blocked for two hours with 5% dry
milk in PBS at room temperature. The membranes were then
incubated with mouse anti-c-myc (Sigma, St. Louis, USA) or
mouse anti-HA (Hiss Diagnostics, Freiburg, Germany) primary
antibodies for 1 h at room temperature. After washing three times
with PBS+0,1% Tween 20 the blots were incubated with
peroxidase-conjugated anti-mouse secondary antibody (Dianova,
Hamburg, Germany) for 1 h at room temperature. After washing
three timeswith PBS+0,1%Tween 20, proteins were detected by
chemiluminescence as indicated by the manufacturers.
Luciferase and β-galactosidase assays
A dual luciferase reporter system (Applied Biosystems,
Foster City, USA) was used to quantify promoter activity. Cells
were harvested 48 h after transfection and were washed twice in
1 ml PBS. 0,1 ml of lysis buffer (Applied Biosystems, Foster
City, USA) was added to the cells and incubated for 5 min at
room temperature. Cells were scraped and collected, and
debris was removed by centrifugation for 1 min at 13,000 rpm
(17900 g) in a microcentrifuge. Supernatants were transferred
to new tubes, and 10 μl of cell lysate was analyzed by
luciferase and β-galactosidase assays using a Microplate
Luminometer (EG and G Berthold, Bad Wildbach, Germany),
according to the manufacturer's instructions (Applied Biosys-
tems). All luciferase activities were normalized to the
corresponding β-galactosidase activities. Fold activation was
calculated by dividing the normalized luciferase activity
stimulated by the pCR-ORFs through the activity stimulated
by the control vector pCR-NS. The normalized luciferase
activity of pCR-NS was assigned an activity of 1.
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